Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US9012462 | TAKEDA PHARMS USA | Phosphorous derivatives as kinase inhibitors |
Apr, 2031
(8 years from now) | |
US10385078 | TAKEDA PHARMS USA | Crystalline forms of 5-chloro-N4-[-2-(dimethylphosphoryl)phenyl]-N2-{2-methoxy-4-[4-(4-methylpiperazin-1-YL) piperidin-1-YL]phenyl}pyrimidine-2,4-diamine |
Nov, 2035
(12 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9273077 | TAKEDA PHARMS USA | Phosphorus derivatives as kinase inhibitors |
May, 2029
(6 years from now) | |
US9611283 | TAKEDA PHARMS USA | Methods for inhibiting cell proliferation in ALK-driven cancers |
Apr, 2034
(11 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | May 22, 2027 |
New Indication (I) | May 22, 2023 |
Market Authorisation Date: 28 April, 2017
Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)
Dosage: TABLET;ORAL
22
United States
9
Japan
5
Korea, Republic of
4
Israel
4
China
4
European Union
3
Mexico
3
Lithuania
3
Hungary
2
Denmark
2
Australia
2
Slovenia
2
Norway
2
Croatia
2
Portugal
2
Spain
2
EA
2
Canada
1
South Africa
1
Hong Kong
1
Philippines
1
Costa Rica
1
Singapore
1
Colombia
1
Brazil
1
Cyprus
1
Netherlands
1
Peru
1
Poland
1
Dominican Republic
1
Chile
1
RS
1
Ecuador
1
Luxembourg
1
Ukraine
1
Tunisia
1
New Zealand
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic